Until now there is no Level of Evidence 1 guideline to which our decision-making can be based on for the management of IIH. A lack of systematic reviews and randomized controlled trials has been noted 1).
Is often ineffective.
A trial of bumetanide (0.25 mg daily) monotherapy was successful in resolution of a patient's symptoms. These results suggest bumetanide could be effective in the treatment of idiopathic intracranial hypertension, perhaps by restoring the balance between cerebrospinal fluid formation and absorption and/or by altering the volume or ionic composition of the brain's extracellular fluid compartment 3).
Acetazolamide and weight loss effectively improve Retinal nerve fiber layer (RNFL) thickness, total retinal thickness (TRT), and optic nerve (ONH) volume swelling measurements resulting from papilledema. In contrast to the strong correlation at baseline, optical coherence tomography (OCT) measures at 6 months show only moderate correlations with papilledema grade 4).